Skip to main content
SpringerLink
Log in

Cognitive Functioning in Schizophrenia

Effects of Drug Treatments

  • Review Articles
  • Drug Therapy
  • Published:
CNS Drugs Aims and scope Submit manuscript

Summary

The presence of a cognitive deficit in patients with schizophrenia has been postulated for over a century, but has only relatively recently become generally accepted. Knowledge of the nature of the deficit may well lead to insights into the pathology of schizophrenia. However, the investigation of cognitive deficits is complicated by the presence of confounding factors, the most important of which is the antipsychotic medication taken by patients with schizophrenia. On a more positive note, if antipsychotic drugs have an effect on the cognitive processes of schizophrenic patients, this in turn may allow a better understanding of the mechanism of action of these drugs.

In this article, we review 30 patient studies that investigated the effect of antipsychotic drugs on tests of cognitive function, including a series focusing on clozapine. The practical difficulties in designing patient studies of this type are profound. In particular, the differences between studies in terms of sample size, time of testing and type of statistical analysis are marked. The presence of important confounding variables is unavoidable; the studies reviewed varied greatly in the type and extent of the efforts taken to control for these variables. Although there is poor consistency between the results of these studies, a trend suggesting that antipsychotics improve cognitive function in patients with schizophrenia is discernable.

The relationship between antipsychotics and laterality is also reviewed. Consistency between results is again poor, and no conclusions can be drawn at this juncture, although the possibility of progress using neuroimaging techniques appears to be promising.

The anticholinergic effects of antipsychotics and other medications are also important, since it is likely that anticholinergic compounds have a detrimental effect on cognition. This can only complicate the investigation of the effect of antipsychotics on cognition, which may be mediated by action at several neuroreceptors. The damaging effect of anticholinergic compounds on cognitive function may have direct clinical implications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. King DJ. The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry 1990; 157: 799–811

    Article  PubMed  CAS  Google Scholar 

  2. Tecce JJ, Cole JO. Psychophysiologic responses of schizophrenics to drugs. Psychopharmacologia 1972; 24: 159–200

    Article  PubMed  CAS  Google Scholar 

  3. Healy D. Neuroleptics and psychic indifference: a review. J R Soc Med 1989; 82: 615–9

    PubMed  CAS  Google Scholar 

  4. Hemsley DR. A two-stage model of attention in schizophrenia research. Br J Soc Clin Psychol 1975; 14: 81–9

    Article  PubMed  CAS  Google Scholar 

  5. Joseph MH, Frith CD, Waddington JL. Dopaminergic mechanisms and cognitive deficit in schizophrenia. Psychopharmacology 1979; 63: 273–80

    Article  PubMed  CAS  Google Scholar 

  6. Berger HJC, van Hoof JJM, van Spaendonck KPM, et al. Haloperidol and cognitive shifting. Neuropsychologia 1989; 27: 629–39

    Article  PubMed  CAS  Google Scholar 

  7. Clark CR, Geffen GM, Geffen LB. Catecholamines and the covert orientation of attention in humans. Neuropsychologia 1989; 27: 131–9

    Article  PubMed  CAS  Google Scholar 

  8. King DJ. Measures of neuroleptic effects on cognition and psychomotor performance in healthy volunteers. In: Hindmarch I, Stonier PD, editors. Human psychopharmacology: measures and methods. Vol. 4. Chichester: John Wiley & Sons Ltd, 1993: 195–209

    Google Scholar 

  9. Heaton RK, Crowley TJ. Effects of psychiatric disorders and their somatic treatments on neuropsychological test results. In: Filskov SB, Boll TJ, editors. Handbook of clinical neuropsychology. Chichester: John Wiley & Sons Ltd, 1981: 481–525

    Google Scholar 

  10. Medalia A, Gold J, Merriam A. The effect of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol 1988; 3: 249–71

    PubMed  CAS  Google Scholar 

  11. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnormal Psychol 1989; 98: 367–80

    Article  CAS  Google Scholar 

  12. Cassens G, Inglis AK, Appelbaum PS, et al. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 1990; 16: 477–99

    PubMed  CAS  Google Scholar 

  13. McKenna PJ, Tamlyn D, Lund CE, et al. Amnesic syndrome in schizophrenia. Psychol Med 1990; 20: 967–72

    Article  PubMed  CAS  Google Scholar 

  14. Tamlyn D, McKenna PJ, Mortimer AM, et al. Memory impairment in schizophrenia: its extent, affiliations and neuropsychological character. Psychol Med 1992; 22: 101–15

    Article  PubMed  CAS  Google Scholar 

  15. Fink M. EEG and human psychopharmacology. Annu Rev Pharmacol 1969; 9: 241–58

    Article  PubMed  CAS  Google Scholar 

  16. Saletu B, Küfferle B, Grünberger J, et al. Quantitative EEG, SPEM, and psychometric studies in schizophrenics before and during differential neuroleptic therapy. Pharmacopsychiatry 1986; 19: 434–7

    Article  PubMed  CAS  Google Scholar 

  17. Saletu B, Grünberger J, Linzmayer L, et al. Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilising pharmaco-EEG and psychometry. Pharmacopsychiatry 1987; 20: 12–27

    Article  PubMed  CAS  Google Scholar 

  18. Merrin EL, Floyd TC, Fein G. Task-related EEG alpha asymmetry in schizophrenic patients prior to and after neuroleptic treatment. Schizophr Res 1988; 1: 283–93

    Article  PubMed  CAS  Google Scholar 

  19. Bartel P, Blom M, van der Meyden C, et al. Effects of single doses of diazepam, chlorpromazine, imipramine and trihexy-phenidyl on visual-evoked potentials. Neuropsychobiology 1988; 20: 212–7

    Article  PubMed  CAS  Google Scholar 

  20. Kemali D, Galderisi S, Maj M, et al. Lateralization patterns of event-related potential and performance indices in schizophrenia: relationship to clinical state and neuroleptic treatment. Int J Psychophysiol 1991; 10: 225–30

    Article  PubMed  CAS  Google Scholar 

  21. Nakagawa M, Takeda K, Kakimoto Y. Characteristic distribution of alpha 2 wave in electroencephalograms of schizophrenic patients during discriminative tasks: support for the hypofrontality hypothesis of schizophrenia. Acta Psychiatr Scand 1991; 83: 105–14

    Article  PubMed  CAS  Google Scholar 

  22. Roth WT, Goodale J, Pfefferbaum A. Auditory event-related potentials and electrodermal activity in medicated and unmedicated schizophrenics. Biol Psychiatry 1991; 29: 585–99

    Article  PubMed  CAS  Google Scholar 

  23. Liddle PF, Friston KJ, Frith CD, et al. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 1992; 160: 179–86

    Article  PubMed  CAS  Google Scholar 

  24. Kornetsky C, Pettit M, Wynne R, et al. A comparison of the psychological effects of acute and chronic administration of chlorpromazine and secobarbital (quinalbarbitone) in schizophrenic patients. J Med Sci 1959; 105: 190–8

    CAS  Google Scholar 

  25. Latz A, Kornetsky C. The effects of chlorpromazine and secobarbital under two conditions of reinforcement on the performance of chronic schizophrenic subjects. Psychopharmacologia 1965; 7: 77–88

    Article  PubMed  CAS  Google Scholar 

  26. Rosvold HE, Mirsky AF, Sarason I, et al. A continuous performance test of brain damage. J Consult Psychol 1956; 20: 343–50

    Article  PubMed  Google Scholar 

  27. Wahba M, Donlon PT, Meadow A. Cognitive changes in acute schizophrenia with brief neuroleptic treatment. Am J Psychiatry 1981; 138: 1307–10

    PubMed  CAS  Google Scholar 

  28. Braff DL, Saccuzzo DP. Effect of antipsychotic medication on speed of information processing in schizophrenic patients. Am J Psychiatry 1982; 139: 1127–30

    PubMed  CAS  Google Scholar 

  29. Walker E. Attentional and neuromotor functions of schizophrenics, schizoaffectives, and patients with other affective disorders. Arch Gen Psychiatry 1981; 38: 1355–8

    Article  PubMed  CAS  Google Scholar 

  30. Walker E. Cognitive changes in schizoaffective patients. Arch Gen Psychiatry 1983; 40: 1255

    Article  Google Scholar 

  31. Erickson WD, Yellin AM, Hopwood JH, et al. The effects of neuroleptics on attention in adolescent schizophrenics. Biol Psychiatry 1984; 19: 745–53

    PubMed  CAS  Google Scholar 

  32. Killian GA, Holzman PS, Davis JM, et al. Effects of psychotropic medication on selected cognitive and perceptual measures. J Abnormal Psychol 1984; 93: 58–70

    Article  CAS  Google Scholar 

  33. Marder SR, Asarnow RF, van Putten T. Information processing and neuroleptic response in acute and stabilized schizophrenic patients. Psychiatry Res 1984; 13: 41–9

    Article  PubMed  CAS  Google Scholar 

  34. Spohn HE, Coyne L, Lacoursiere R, et al. Relation of neuroleptic dose and tardive dyskinesia to attention, information-processing and psychophysiology in medicated schizophrenics. Arch Gen Psychiatry 1985; 42: 849–59

    Article  PubMed  CAS  Google Scholar 

  35. Spohn HE, Coyne L, Mittleman F, et al. Effect of neuroleptic treatments on attention, information processing, and thought disorder. Psychopharmacol Bull 1985; 21: 582–7

    PubMed  CAS  Google Scholar 

  36. Strauss ME, Lew MF, Coyle JT, et al. Psychopharmacologic and clinical correlates of attention in chronic schizophrenia. Am J Psychiatry 1985; 142: 497–9

    PubMed  CAS  Google Scholar 

  37. Berman KF, Zec RF, Weinberger DR. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia: II. Role of neuroleptic treatment, attention, and mental effort. Arch Gen Psychiatry 1986; 43: 126–35

    Article  PubMed  CAS  Google Scholar 

  38. Fields RB, van Kammen DP, Peters JL, et al. Clonidine improves memory function in schizophrenia independently from change in psychosis. Schizophr Res 1988; 1: 417–23

    Article  PubMed  CAS  Google Scholar 

  39. Bartkö G, Frecska E, Zador G, et al. Neurological features, cognitive impairment and neuroleptic response in schizophrenic patients. Schizophr Res 1989; 2: 311–3

    Article  PubMed  Google Scholar 

  40. Calvert JE, Babiker IE, Harris JP, et al. Object-name selection in psychiatric patients before and after neuroleptic therapy. J Psychopharmacol 1990; 4: 75–82

    Article  PubMed  CAS  Google Scholar 

  41. Cleghorn JM, Kaplan RD, Szechtman B, et al. Neuroleptic drug effects on cognitive function in schizophrenia. Schizophr Res 1990; 3: 211–9

    Article  PubMed  CAS  Google Scholar 

  42. Cutmore TRH, Beninger RJ. Do neuroleptics impair learning in schizophrenic patients? Schizophr Res 1990; 3: 173–86

    Article  PubMed  CAS  Google Scholar 

  43. Gold JM, Hurt SW. The effects of haloperidol on thought disorder and IQ in schizophrenia. J Personality Assess 1990; 54: 390–400

    Article  CAS  Google Scholar 

  44. Harvey PD, Keefe RSE, Moskowitz J, et al. Attentional markers of vulnerability to schizophrenia: performance of medicated and unmedicated patients and normals. Psychiatry Res 1990; 33: 179–88

    Article  PubMed  CAS  Google Scholar 

  45. Serper MR, Bergman RL, Harvey PD. Medication may be required for the development of automatic information processing in schizophrenia. Psychiatry Res 1990; 32: 281–8

    Article  PubMed  CAS  Google Scholar 

  46. Earle-Boyer EA, Serper MR, Davidson M, et al. Continuous performance tests in schizophrenic patients: stimulus and medication effects on performance. Psychiatry Res 1991; 37: 47–56

    Article  PubMed  CAS  Google Scholar 

  47. Goldberg TE, Bigelow LB, Weinberger DR, et al. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiatry 1991; 148: 78–84

    PubMed  CAS  Google Scholar 

  48. Nestor PG, Faux SF, McCarley RW, et al. Neuroleptics improve sustained attention in schizophrenia: a study using signal detection theory. Neuropsychopharmacology 1991; 4: 145–9

    PubMed  CAS  Google Scholar 

  49. Seidman LJ, Pepple JR, Faraone SV, et al. Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction. Biol Psychiatry 1993; 33: 575–84

    Article  PubMed  CAS  Google Scholar 

  50. Classen W, Laux G. Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupen-thixol, or clozapine. Pharmacopsychiatry 1988; 21: 295–7

    Article  PubMed  CAS  Google Scholar 

  51. Classen W, Laux G. Comparison of sensorimotor and cognitive performance of acute schizophrenic inpatients treated with remoxipride or haloperidol. Neuropsychobiology 1989; 21: 131–40

    Article  PubMed  CAS  Google Scholar 

  52. Strauss WH, Klieser E. Cognitive disturbances in neuroleptic therapy. Acta Psychiatr Scand 1990; 82 Suppl. 358: 56–7

    Article  Google Scholar 

  53. Goldberg TE, Greenberg RD, Griffin SJ, et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 1993; 162: 43–8

    Article  PubMed  CAS  Google Scholar 

  54. Hagger C, Buckley P, Kenny JT, et al. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993; 34: 702–12

    Article  PubMed  CAS  Google Scholar 

  55. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994; 36: 717–25

    Article  PubMed  CAS  Google Scholar 

  56. Zahn TP, Pickar D, Haier RJ. Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophr Res 1994; 13: 133–44

    Article  PubMed  CAS  Google Scholar 

  57. Spohn HE, Lacoursiere RB, Thompson K, et al. Phenothiazine effects on psychological and psychophysiological dysfunction in chronic schizophrenics. Arch Gen Psychiatry 1977; 34: 633–44

    Article  PubMed  CAS  Google Scholar 

  58. Oades RD. Attention and schizophrenia: neurobiological bases. London: Pitman Books Limited, 1982: 30–6

    Google Scholar 

  59. Posner MI, Walker JA, Friedrich FA, et al. How do the parietal lobes direct covert attention? Neuropsychologia 1987; 25: 135–45

    Article  PubMed  CAS  Google Scholar 

  60. Posner MI, Petersen SE, Fox PT, et al. Localization of cognitive operations in the human brain. Science 1988; 240: 1627–31

    Article  PubMed  CAS  Google Scholar 

  61. Posner MI, Petersen SE. The attention system of the human brain. Annu Rev Neurosci 1990; 13: 25–42

    Article  PubMed  CAS  Google Scholar 

  62. Oades RD. Attention and schizophrenia: neurobiological bases. London: Pitman Books Limited, 1982: 159–72

    Google Scholar 

  63. Waddington JL. Tardive dyskinesia in schizophrenia and other disorders: associations with ageing, cognitive dysfunction and structural brain pathology in relation to neuroleptic exposure. Hum Psychopharmacol 1987; 2: 11–22

    Article  Google Scholar 

  64. Collerton D, Fairbairn A, Britton P. Cognitive performance of medicated schizophrenics with tardive dyskinesia. Psychol Med 1985; 15: 311–5

    Article  PubMed  CAS  Google Scholar 

  65. Myslobodsky MS, Tomer R, Holden T, et al. Cognitive impairment in patients with tardive dyskinesia. J Nerv Ment Dis 1985; 173: 156–60

    Article  PubMed  CAS  Google Scholar 

  66. Marsalek M, Pavlat DJ, Petrovsky M, et al. The signs of brain vulnerability in tardive dyskinesia. Schizophr Res 1988; 1: 231

    Article  Google Scholar 

  67. Soni SD, Neill D, Sheffield B. Cognitive functions in chronic schizophrenic patients with tardive dyskinesia. Hum Psychopharmacol 1993; 8: 233–42

    Article  Google Scholar 

  68. Barnes TRE, Crichton P, Nelson HE, et al. Primitive developmental reflexes, tardive dyskinesia and intellectual impairment in schizophrenia. Schizophr Res 1995; 16: 47–52

    Article  PubMed  CAS  Google Scholar 

  69. Waddington JL, O’Callaghan E, Buckley P, et al. Tardive dyskinesia in schizophrenia — relationship to minor physical anomalies, frontal lobe dysfunction and cerebral structure on magnetic resonance imaging. Br J Psychiatry 1995; 167: 41–4

    Article  PubMed  CAS  Google Scholar 

  70. Crow TJ. Molecular pathology of schizophrenia: more than one disease process? BMJ 1980; 280: 66–8

    Article  PubMed  CAS  Google Scholar 

  71. Gruzelier JH, Seymour K, Wilson L, et al. Impairments on neuropsychologic tests of temporohippocampal and fronto-hippocampal function and word fluency in remitting schizophrenia and affective disorders. Arch Gen Psychiatry 1988; 45: 623–9

    Article  PubMed  CAS  Google Scholar 

  72. Tomer R, Mintz M, Myslobodsky MS. Left hemisphere hyper-activity in schizophrenia: abnormality inherent to psychosis or neuroleptic side-effects? Psychopharmacology 1982; 77: 168–70

    Article  PubMed  CAS  Google Scholar 

  73. Tomer R, Flor-Henry P. Neuroleptics reverse attention asymmetries in schizophrenic patients. Biol Psychiatry 1989; 25: 852–60

    Article  PubMed  CAS  Google Scholar 

  74. Tomer R. Neuroleptic effects on interhemispheric and intrahemispheric performance of tactile discrimination tasks by schizophrenic patients. Psychiatry Res 1990; 32: 289–96

    Article  PubMed  CAS  Google Scholar 

  75. Frazier MF, Silverstein ML, Fogg L. Lateralized cerebral dysfunction in schizophrenia and depression: gender and medication effects. Arch Clin Neuropsychol 1989; 4: 33–44

    PubMed  CAS  Google Scholar 

  76. Seidman LJ. Schizophrenia and brain dysfunction: an integration of recent neuro-diagnostic findings. Psychol Bull 1983; 94: 195–238

    Article  PubMed  CAS  Google Scholar 

  77. Tune LE, Strauss ME, Lew MF, et al. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am J Psychiatry 1982; 139: 1460–2

    PubMed  CAS  Google Scholar 

  78. Katz IR, Greenberg WH, Barr GA, et al. Screening for cognitive toxicity of anticholinergic drugs. J Clin Psychiatry 1985; 46: 323–6

    PubMed  CAS  Google Scholar 

  79. Perlick D, Stastny P, Katz I, et al. Memory deficits and anticholinergic levels in chronic schizophrenia. Am J Psychiatry 1986; 143: 230–2

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Therapeutics and Pharmacology, The Queen’s University of Belfast, Whitla Medical Building, 97 Lisburn Road, Belfast, BT9 7BL, Northern Ireland

    Jonathan F. Green &  David J. King

  2. Holywell Hospital, Antrim, Northern Ireland

    David J. King

Authors
  1. Jonathan F. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David J. King
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Green, J.F., King, D.J. Cognitive Functioning in Schizophrenia. CNS Drugs 6, 382–398 (1996). https://doi.org/10.2165/00023210-199606050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-199606050-00005

Keywords

Search

Navigation